Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving separate clinical trial approvals from China’s National Medical Products Administration (NMPA) for its two drug candidates, SHR-4394 and HRS-3802.
SHR-4394: A Novel Therapeutic Biologic for Prostate Cancer
SHR-4394 is an in-house developed therapeutic biologic product, with its target undisclosed, currently under development for the treatment of prostate cancer. The clinical trial approval from the NMPA marks a significant step forward in bringing this potential treatment to patients suffering from prostate cancer in China.
HRS-3802: A Cyclin Dependent Kinase (CDK) Inhibitor for Tumor Treatment
HRS-3802 is a cyclin dependent kinase (CDK) inhibitor, a class of drugs used to treat various types of tumors by inhibiting the activity of CDKs, which play a crucial role in cell cycle regulation. The approval of HRS-3802’s clinical trial highlights Jiangsu Hengrui Pharmaceuticals’ commitment to expanding treatment options for cancer patients.
Global First-in-Class Potential for Both Drugs
Neither SHR-4394 nor HRS-3802 has any comparable products approved for marketing worldwide, indicating the potential for these drugs to be first-in-class treatments. This underscores the innovation and research capabilities of Jiangsu Hengrui Pharmaceuticals in developing new therapies for unmet medical needs.-Fineline Info & Tech
